Form 4: Cryoport CEO Shelton Sells Shares, Acquires Options

Cryoport's President and CEO, Jerrell Shelton, reported the sale of 7,918 common shares for tax purposes and the acquisition of 492,901 stock options.

Summary

• Jerrell Shelton, President, CEO, and Director of Cryoport, Inc. (CYRX), reported transactions involving the company's securities.
• On March 16, 2026, 7,918 shares of common stock were disposed of directly at a price of $8 per share.
• This sale was required to cover tax obligations upon the vesting of restricted stock rights, in accordance with company policies.
• Following this transaction, Jerrell Shelton beneficially owns 1,054,501 shares of common stock directly.
• On March 14, 2026, 492,901 stock options (right to buy) were acquired directly, with an exercise price of $8.6 per share.
• These options begin vesting on April 14, 2026, with 1/48 of the options vesting on the 14th of each month for forty-eight months.
• The stock options have an expiration date of March 14, 2033.
• Following this acquisition, Jerrell Shelton beneficially owns 492,901 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction. The acquisition of a significant number of stock options indicates continued long-term incentive for the CEO, while the share sale is a standard procedure for covering tax obligations, leading to a neutral to slightly positive sentiment.

Positives

• The acquisition of 492,901 stock options aligns the CEO's long-term incentives with shareholder value, as the options vest over a four-year period and have an exercise price above the sale price of the common stock.

Negatives

• The direct sale of 7,918 common shares, although for tax purposes, reduces the CEO's direct equity ownership in the company.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on insider transactions.

Industry Context

StockSavvy.ai notes that insider transactions, such as the grant of stock options and subsequent tax-related sales of common stock, are routine components of executive compensation packages in publicly traded companies. The grant of options serves as a long-term incentive, while tax-related sales are a common mechanism for executives to cover tax liabilities arising from equity vesting.

Comparison to Industry Standards

• Executive compensation structures across the industry frequently include equity components like restricted stock and stock options to align management interests with shareholder returns.
• Tax-related sales upon the vesting of restricted stock are a standard practice for executives in many companies, including peers in the life sciences logistics sector, to manage personal tax obligations without necessarily indicating a change in sentiment towards the company's prospects.

Stakeholder Impact

• Shareholders may view the option grant as a positive, aligning the CEO's future financial interests with the company's stock performance over the long term.
• The tax-related sale of shares is generally considered a neutral event for shareholders, as it is a common practice for executives managing their compensation.

Next Steps

• The acquired stock options will begin vesting on April 14, 2026, and continue monthly for 48 months.

Key Dates

Recommendation

This Form 4 details routine insider transactions for Cryoport's CEO, involving a tax-related sale of shares and the grant of stock options. Such transactions are common and generally do not signal a fundamental shift in the company's prospects or warrant a change in investment thesis. The option grant aligns management's interests with long-term shareholder value, supporting a 'hold' recommendation for existing investors.

Keywords

Cryoport, CYRX, Jerrell Shelton, Insider Transaction, Form 4, Stock Options, Share Sale, CEO, Director, Beneficial Ownership